BMS-303141
ATP citrate lyase (ACL) inhibitor / Potent and selective ATP citrate lyase (ACL) inhibitor, IC50=0.13 uM. Inhibits lipid biosynthesis, IC50=8 uM in HepG2 cells.1,2 Reduces weight gain, lowers plasma cholesterol, triglycerides and glucose in high-fat-fed mice.2 A novel tool compound for exploring the potential of ACL inhibition as a target for metabolic disorders such as obesity and dyslipidemia.2 Impairs proliferation or induces death in androgen-depleted castration resistant prostate cancer cells.3 Reduces cell cycle progression in iBN cells.4
Biochemicals & reagents
943962-47-8
ACLYi
1) Li et al. (2007), 2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors; Bioorg. Med. Chem., 17 3208 2) Ma et al. (2009), A novel direct homogeneous assay for ATP citrate lyase; J. Lipid Res., 50 2131 3) Shah et al. (2016), Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism; Oncotarget, 7 43713 4) Rhee and Dekoter et al. (2017), Regulation of Lipid Metabolism and Cell Cycle Progression by PU.1 in Myeloid Progenitor Cells; Blood, 130 2433
-20°C
PATHWAY: Cell cycle; Carbohydrate metabolism; Proliferation; AMPK; Lipid metabolism -- RESEARCH AREA: Cell death -- DISEASE AREA: Obesity; DiabetesCancer